DeepMed Research

Eastern Cooperative Oncology Group

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private, Subsidiary

Established: 2012-01-01

Employees: 51

Market Cap: -

Website: https://ecog-acrin.org

Clinical Trials

Extended Clinical Follow up and Biospecimen Collection for Patients Enrolled in TAILORx and RxPONDER: A Companion Protocol

Not yet recruiting

Conditions: Breast Cancer

First Posted Date: 2025-01-22

Last Posted Date: 2025-01-22

Lead Sponsor: Eastern Cooperative Oncology Group

Target Recruit Count: 600

Registration Number: NCT06786585

The ECOG-ACRIN SUPPORT Trial: Multilevel Intervention to Improve Diverse Enrollment in Cancer Clinical Trials

Not Applicable

Recruiting

Conditions: Cancer

First Posted Date: 2025-01-03

Last Posted Date: 2025-05-09

Lead Sponsor: Eastern Cooperative Oncology Group

Target Recruit Count: 500

Registration Number: NCT06756607

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States

Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

Phase 3

Not yet recruiting

Conditions: Anaplastic Large Cell Lymphoma, ALK-Negative
Follicular Helper T-Cell Lymphoma
Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type
Peripheral T-Cell Lymphoma, Not Otherwise Specified

Interventions: Other: Best Practice
Procedure: Autologous Hematopoietic Stem Cell Transplantation
Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Procedure: Computed Tomography
Procedure: Positron Emission Tomography
Drug: High Dose Chemotherapy
Procedure: Leukapheresis
Drug: Stem Cell Mobilization Therapy

First Posted Date: 2024-12-09

Last Posted Date: 2024-12-09

Lead Sponsor: Eastern Cooperative Oncology Group

Target Recruit Count: 294

Registration Number: NCT06724237

Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia (AML) Following Initial Treatment

Phase 2

Not yet recruiting

Conditions: Leukemia, Myeloid, Acute

Interventions: Drug: Cytarabine
Drug: CPX-351
Drug: Azacitidine
Drug: Venetoclax

First Posted Date: 2022-11-28

Last Posted Date: 2024-07-03

Lead Sponsor: Eastern Cooperative Oncology Group

Target Recruit Count: 184

Registration Number: NCT05628623

Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL

Phase 2

Recruiting

Conditions: T-cell Acute Lymphoblastic Leukemia

Interventions: Drug: Daratumumab / Hyaluronidase Injection

First Posted Date: 2022-03-21

Last Posted Date: 2024-12-12

Lead Sponsor: Eastern Cooperative Oncology Group

Target Recruit Count: 20

Registration Number: NCT05289687

Locations: 🇺🇸
Northwestern, Chicago, Illinois, United States

Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials

Not Applicable

Recruiting

Conditions: Cervical Cancer, NOS
Miscellaneous Neoplasm, NOS
Bone Cancer, NOS
Non-Rhabdomyosarcoma Soft Tissue Sarcoma, NOS
Melanoma
Breast Cancer, NOS
Testicular Nonseminomatous Germ Cell Tumor, NOS
CNS Primary Tumor, NOS
Lymphoma, NOS
Thyroid Cancer, NOS

Interventions: Other: Questionnaires

First Posted Date: 2021-11-04

Last Posted Date: 2024-10-30

Lead Sponsor: Eastern Cooperative Oncology Group

Target Recruit Count: 400

Registration Number: NCT05108298

Locations: 🇺🇸
Grant Medical Center, Columbus, Ohio, United States
🇺🇸
Flaget Memorial Hospital, Bardstown, Kentucky, United States
🇺🇸
Saint Joseph London, London, Kentucky, United States

and more 341 locations

COVID-19 Related Financial Hardship and Distress in Women Who Decline TMIST (EA1151) Participation

Terminated

Conditions: Breast Cancer, NOS

Interventions: Other: Questionnaire

First Posted Date: 2021-10-13

Last Posted Date: 2025-03-25

Lead Sponsor: Eastern Cooperative Oncology Group

Target Recruit Count: 14

Registration Number: NCT05076266

Locations: 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States

Phase III rhu_GM-CSF + 3 Induction Regimens in Adults With Acute Non-Lymphocytic Leukemia

Phase 3

Completed

Conditions: Adult Patients (Over 55) With Acute Non-Lymphocytic Leukemia

Interventions: Drug: Placebo
Drug: GM-CSF priming

First Posted Date: 2020-06-24

Last Posted Date: 2023-06-22

Lead Sponsor: Eastern Cooperative Oncology Group

Target Recruit Count: 362

Registration Number: NCT04446052

Double Blind Phase III Trial of Effects of Low Dose 13-Cisretinoic Acid on Prevention of Second Primaries in Stages I-II Head and Neck Cancer

Phase 3

Completed

Conditions: Stage I-II Head and Neck Cancer

Interventions: Drug: 13-cis retinoic acid
Other: Placebo

First Posted Date: 2017-12-12

Last Posted Date: 2023-06-15

Lead Sponsor: Eastern Cooperative Oncology Group

Target Recruit Count: 189

Registration Number: NCT03370367

C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer

Phase 1

Withdrawn

Conditions: Stage IIIA Esophageal Cancer
Stage IIIA Gastric Cancer
Stage IIIB Esophageal Cancer
Stage IIIB Gastric Cancer
Adenocarcinoma of the Esophagus
Intestinal Adenocarcinoma of the Stomach
Adenocarcinoma of the Gastroesophageal Junction
Mixed Adenocarcinoma of the Stomach
Stage IIIC Esophageal Cancer
Stage IIIC Gastric Cancer

Interventions: Drug: c-Met inhibitor AMG 337
Other: placebo
Drug: oxaliplatin
Drug: leucovorin calcium
Drug: fluorouracil
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2015-01-26

Last Posted Date: 2023-05-25

Lead Sponsor: Eastern Cooperative Oncology Group

Registration Number: NCT02344810

Locations: 🇺🇸
ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy